The Diabetic Investor Top Ten
Although we’re not big fans of the Letterman show, we do like the Top Ten lists. Due to recent events we’ve decided to come up with our own top ten list; The Ten Dumbest Moves In Diabetes.
1. Exubera – that multi-billion product that in reality is a million dollar product
2. Abbott Diabetes Care – actually Abbott should receive two nominations, one for running Therasense into the ground, the other for how they handled the Navigator (FYI- we are still accepting entries into our other contest; Guess the date Navigator receives FDA approval)
3. Changing A1c from a simple number that everyone understands to a complex number that no one understands.
4. Medtronic – forming an alliance that will do little to sell more pumps but will likely benefit their number one competitor in the insulin pump market.
5. Johnson and Johnson- spend nearly $550 million to acquire an insulin pump company, already own the number one blood glucose monitoring company, come out with a new pump that doesn’t communicate with your line of meters and them form an alliance that allows your meters to communicate with your main competitor and market leader in the insulin pump market.
6. Using surgery to treat type 2 diabetes
7. Roche – spend over a billion dollars to acquire an insulin pump company, get the product pulled from the U.S. market and then come out with a new pump that’s technology inferior to what’s already on the market
8. The GlucoWatch or the Amira At-Last meter – take your pick
9. Any company that still believes in non-invasive glucose monitoring or anyone who still thinks non-invasive monitoring would get non-insulin patients to check their levels
10. Anyone who still believes patients won’t use Byetta because it must be injected.